Page 2 - Decision Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Decision Diagnostics (OTCMKTS:DECN – Get Rating) and Doximity (NASDAQ:DOCS – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Earnings & Valuation This table compares Decision Diagnostics and Doximity’s revenue, […]

Decision Diagnostics (OTCMKTS:DECN – Get Rating) and Perficient (NASDAQ:PRFT – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Valuation and Earnings This table compares Decision Diagnostics and Perficient’s revenue, […]

Decision Diagnostics (OTCMKTS:DECN – Get Rating) and PROS (NYSE:PRO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Institutional & Insider Ownership 0.0% of Decision Diagnostics shares are […]

To print this article, all you need is to be registered or login on Mondaq.com. In December, the SEC filed a  complaint against Decision Diagnostics and its CEO, Keith Berman, for falsely claiming the company had developed a finger prick blood test that could instantaneously detect COVID-19.  As stated in its complaint, the SEC temporarily suspended trading of Decision Diagnostics' securities on April 23, 2020. Now, investors have brought suit as well.  Three institutional investors  claim the company – which was already in financial distress as a result of ...

Share this article Share this article NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Decision Diagnostics securities between March 3, 2020 and December 17, 20...